SCHEMBL19283293

SCHEMBL19283293

COc1cccc(/C=N/NC(=O)c2ccc(O)cc2)c1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.80
KDM4E B2RXH2 10/20 0.80
HTT P42858 6/20 0.80
KMT2A Q03164 6/20 0.80
SMN1; SMN2 Q16637 5/20 0.80
LMNA P02545 4/20 0.80
MEN1 O00255 4/20 0.80
NPC1 O15118 3/20 0.80
L3MBTL1 Q9Y468 2/20 0.73
POLB P06746 1/20 0.73
RECQL P46063 1/20 0.73
TDP1 Q9NUW8 3/20 0.69
GCGR P47871 1/20 0.68
PKM P14618 3/20 0.67
MAPK1 P28482 1/20 0.63
KDM1A O60341 1/20 0.63
MAOA P21397 1/20 0.63
MAOB P27338 1/20 0.63
RAB9A P51151 2/20 0.62
MITF O75030 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16035430 1.00 MAPT (0.80) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL14907041 1.00 MAPT (0.80) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL14949043 0.91 MAPT (0.78) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL28800595 0.91 MAPT (0.78) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL13617293 0.91 MAPT (0.86) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL683795 0.91 MAPT (0.86) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL28295711 0.90 MAPT (0.84) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL19283314 0.89 MAPT (0.78) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL19283312 0.89 MAPT (0.78) MAPTKDM4EHTTKMT2ASMN1; SMN2
SCHEMBL28800601 0.89 MAPT (0.82) MAPTKDM4EHTTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170246130-A1 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS CHOUDHARY MUHAMMAD IQBAL (PK) 2017-08-31 US claimed
US-20170246130-A1 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS CHOUDHARY MUHAMMAD IQBAL (PK) 2017-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170246130-A1 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS TYMP, DPYD, FLT4 MAPT 4301/4885KDM4E 163/4885HTT 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.